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Neurofibromatosis-1 regulates neuroglial
progenitor proliferation and glial
differentiation in a brain
region-specific manner
Da Yong Lee,1 Tu-Hsueh Yeh,1,2 Ryan J. Emnett,1 Crystal R. White,1 and David H. Gutmann1,3
1
Department of Neurology, Washington University School of Medicine, St. Louis, Missouri 63110, USA; 2Department
of Neurology, Chang Gung Memorial Hospital and University, Taipei 10591, Taiwan

Recent studies have shown that neuroglial progenitor/stem cells (NSCs) from different brain regions exhibit
varying capacities for self-renewal and differentiation. In this study, we used neurofibromatosis-1 (NF1) as a model
system to elucidate a novel molecular mechanism underlying brain region-specific NSC functional heterogeneity.
We demonstrate that Nf1 loss leads to increased NSC proliferation and gliogenesis in the brainstem, but not in the
cortex. Using Nf1 genetically engineered mice and derivative NSC neurosphere cultures, we show that this brain
region-specific increase in NSC proliferation and gliogenesis results from selective Akt hyperactivation. The
molecular basis for the increased brainstem-specific Akt activation in brainstem NSCs is the consequence of
differential rictor expression, leading to region-specific mammalian target of rapamycin (mTOR)/rictor-mediated
Akt phosphorylation and Akt-regulated p27 phosphorylation. Collectively, these findings establish mTOR/rictormediated Akt activation as a key driver of NSC proliferation and gliogenesis, and identify a unique mechanism for
conferring brain region-specific responses to cancer-causing genetic changes.
[Keywords: Neurofibromin; neural stem cell; regional heterogeneity; gliogenesis; Akt; mTOR]
Supplemental material is available at http://www.genesdev.org.
Received June 7, 2010; revised version accepted August 25, 2010.

The capacity of neural stem/progenitor cells (NSCs) to
self-renew, proliferate, and give rise to differentiated cell
types is essential for normal brain development and
maturation. In addition, NSCs have critical roles in numerous pathological states, including the response to nervous system injury, neurodegenerative disease, and brain
tumor formation (Corbin et al. 2008; Waldau and Shetty
2008; Alcantara Llaguno et al. 2009; Yadirgi and Marino
2009). Recent studies have shown that NSCs from different
regions of the CNS exhibit varying abilities to divide
and generate lineage-restricted progeny (Klein et al. 2005;
Armando et al. 2007). In these studies, NSCs from the
forebrain proliferated faster than those from the hindbrain
(Horiguchi et al. 2004; Kim et al. 2006) or spinal cord
(Fu et al. 2005) and exhibited differing abilities to produce
radial glia (Kulbatski and Tator 2009) and glial fibrillary
acidic protein (GFAP)-positive cells (astrocytes) in vitro
(Hitoshi et al. 2002). However, it is not known whether
these intrinsic region-restricted NSC properties have relevance to human disease pathogenesis.
3
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While brain tumors can arise in any location in the
CNS in adults, glial cell tumors (astrocytomas or gliomas)
are most frequently observed in the cerebellum, brainstem (BS), and optic pathway/hypothalamus in children
(Louis et al. 2007). This anatomic predisposition is best
illustrated by the neurofibromatosis-1 (NF1) inherited
cancer syndrome, in which low-grade astrocytomas are
located predominantly in the optic pathway/hypothalamus
and BS of young children, with rare tumors developing in
the cerebral cortex (Listernick et al. 1994; Pollack et al.
1996; Guillamo et al. 2003). In light of studies implicating
cells with stem cell-like properties in the genesis of astrocytoma (for review, see Stiles and Rowitch 2008), it is
conceivable that this regional distribution of tumors partly
reflects the intrinsic heterogeneity of stem cells from different regions of the brain to expand in response to cancerassociated genetic changes. Based on the unique spatial
distribution of gliomas in children with NF1, we chose to
employ Nf1 genetically engineered mice and derivative
NSCs to define the molecular basis for NSC heterogeneity
in the brain.
NF1 is the most common cancer predisposition syndrome in which affected children develop gliomas. NF1associated gliomas result from biallelic inactivation of
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the NF1 tumor suppressor gene, leading to total loss of
NF1 protein (neurofibromin) function. Neurofibromin
is a large cytoplasmic protein that negatively regulates
RAS pathway signaling by inactivating the RAS protooncogene such that loss of NF1 gene expression is
associated with increased RAS and RAS effector (Akt
and MAPK) activity (Basu et al. 1992; DeClue et al. 1992).
As predicted, examination of gliomas from individuals
with NF1 confirmed loss of NF1 expression and increased RAS pathway activation (Gutmann et al. 2000;
Lau et al. 2000). Similarly, Nf1-deficient primary mouse
forebrain astrocytes exhibit high levels of RAS activation,
resulting in increased Akt and mammalian target of
rapamycin (mTOR) signaling (Dasgupta et al. 2005b;
Sandsmark et al. 2007). Inhibition of Akt/mTOR activity
in Nf1 / astrocytes restores their proliferation to wildtype levels in vitro and blocks optic glioma growth in
vivo (Hegedus et al. 2008).
Previous studies have shown that neurofibromin is an
important regulator of NSC function. In this regard, Nf1
inactivation leads to an expansion in the number of proliferating spinal cord progenitors (Bennett et al. 2003),
while Nf1 / neural crest stem cells exhibit increased
proliferation relative to their wild-type counterparts
(Joseph et al. 2008). Similarly, Nf1 / embryonic telencephalic NSCs exhibit increased proliferation in vitro
(Dasgupta and Gutmann 2005), while Nf1 inactivation
in brain lipid-binding protein (BLBP)-expressing neuroglial progenitors in vivo results in increased NSC proliferation and glial lineage differentiation (Hegedus et al.
2007). Moreover, the effect of neurofibromin loss on
NSC glial differentiation was dependent on RAS and
Akt signaling, and could be recapitulated by the expression of either activated K-RAS or Akt in BLBP+ cells in
vivo.
In this study, we describe regional differences in brain
NSC proliferation and glial differentiation following Nf1
gene inactivation in vitro and in vivo. Whereas Nf1 /
NSCs from the BS exhibit increased proliferation and glial
cell differentiation in vitro and in vivo, we observed no
effect of Nf1 gene inactivation on neocortex (CTX) NSC
proliferation or gliogenesis. We further show that these
cell-autonomous differences reflect the ability of BS NSCs
to activate Akt in an mTOR/rictor-dependent fashion and
culminate in Akt-mediated p27 phosphorylation. Collectively, these results demonstrate that intrinsic differences
in NSC signaling cause brain region-specific abnormalities
in glial differentiation, which may partially account for the
propensity of glial cell tumors to arise in the BS of children
with NF1.
Results
Nf1 inactivation results in increased BS NSC
proliferation
Recently, we showed that Nf1 inactivation results in the
increased proliferation of astrocytes from some brain
regions (BS, optic nerve [ON], and cerebellum), whereas
CTX astrocyte proliferation is unaffected by Nf1 loss (Yeh
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et al. 2009). Since gliomas have been hypothesized to
originate from cells with stem cell-like properties, we
generated neurosphere cultures from several regions of the
postnatal brain. The ON and BS were chosen to represent
regions where gliomas arise in children with NF1, while
the CTX was included as a region where glioma formation
is far less common. We used these different neurosphere
populations to determine whether Nf1 loss had differential
effects on NSC proliferation and gliogenesis as a function
of brain region.
NSCs are defined as neurosphere cultures that express
stem cell markers (e.g., BLBP and nestin) and retain the
ability to undergo self-renewal and multi-lineage differentiation. For these experiments, we generated neurosphere cultures from postnatal day 1 (PN1) mouse CTX,
BS, and ON. All of the resulting neurospheres from the
CTX and BS were BLBP- and nestin-immunoreactive (Supplemental Fig. S1A). However, ON neurosphere cultures
had limited capacity for proliferation and self-renewal
(Supplemental Fig. S1B,C), and failed to generate Tuj-1+
neurons or O4+ oligodendrocytes (Supplemental Fig.
S1D). In contrast, both CTX and BS neurospheres were
capable of self-renewal, and generated neurons (Tuj-1+),
astrocytes (GFAP+), and oligodendrocytes (O4+) (Supplemental Fig. S1E). Based on these results, ON neurospheres contained only glial progenitor cells and could
not be classified as ‘‘true’’ NSCs. Therefore, we focused
our analyses on NSCs from the BS and CTX as representative populations that derive from regions where gliomas commonly and rarely form, respectively, in children
with NF1.
To determine whether Nf1 inactivation has different
effects on CTX versus BS NSC proliferation, we first
measured neurofibromin levels to exclude brain regionspecific differences in overall Nf1 gene expression and
found equivalent levels of neurofibromin expression
(Supplemental Fig. S2A). Second, using Nf1 / and wildtype NSC cultures from PN1 Nf1flox/flox mouse CTX and
BS neurosphere cultures following Cre or LacZ gene
adenovirus (Ad5) infection, respectively, Nf1 / BS NSCs
exhibited a 1.9-fold increased in proliferation compared
with wild-type BS NSCs (Fig. 1A; Supplemental Fig. S2A).
In contrast, there was no increase in CTX NSC proliferation after Nf1 inactivation. To demonstrate that
these observations were not dependent on the developmental age or the method of Nf1 inactivation, we used
Nf1 / NSCs generated from PN1 Nf1flox/flox; BLBP-Cre
(Nf1BLBPCKO) mice as well as embryonic day 13.5 (E13.5)
Nf1 / NSCs following Ad5-Cre infection. Compared with
their matched wild-type counterparts, these Nf1 / NSCs
from the BS, but not the CTX, also exhibited increased
proliferation (Fig. 1A). No change in self-renewal was observed in either BS or CTX NSCs following Nf1 inactivation (Supplemental Fig. S2B).
Next, to assess the impact of Nf1 inactivation on NSCs
in the subventricular zone (SVZ), an important germinal
zone for neurogenesis in both adults and children, we
isolated NSCs from the SVZ of PN1 mice. Whereas neurofibromin loss in BS NSCs resulted in a 1.8-fold increase
in NSC proliferation, NSC proliferation was increased by
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Figure 1. Nf1 inactivation increases BS NSC proliferation. (A) Nf1 loss results in increased BS NSC neurosphere size, with no effect on CTX NSCs. Identical
results were obtained with PN1 NSCs following acute
Nf1 inactivation with Ad5-Cre (Cre), PN1 NSCs from
Nf1BLBPCKO mice, or E13.5 NSCs after Nf1 inactivation.
For controls, Nf1flox/flox NSCs were infected with Ad5LacZ (LacZ). Phase contrast images show representative
neurospheres, which are graphically illustrated below.
Similarly, increased numbers of BLBP+ cells by immunofluorescence were observed in the BS of PN1 (B) and PN8
(C) mice, with no increase seen in the CTX. Sections
were counterstained with DAPI. Graphs show the number of BLBP+ cells per surface area (0.1 mm2). Values
denote the mean 6 SEM. (*) P < 0.05. Bars: A, 300 mm;
B,C, 100 mm.

1.4-fold in SVZ NSCs in vitro (Supplemental Fig. S2C).
Similarly, the number of proliferating (Ki67+) cells was
increased by 2.8-fold in the BS of Nf1BLBPCKO mice compared with wild-type controls in vivo, while the number
of Ki67+ cells in the SVZ was increased by only 1.3-fold
(Supplemental Fig. S2D).
Finally, to demonstrate that this effect on NSC proliferation was also seen in vivo, the impact of Nf1 inactivation on the numbers of BLBP+ cells in PN1 and PN8
Nf1BLBPCKO mice was examined. Similar to the in vitro
results, increased numbers of BLBP+ cells were observed
in the BS of Nf1BLBPCKO mice at PN1 (1.5-fold) (Fig. 1B)
and PN8 (1.3-fold) (Fig. 1C), whereas no significant change
in BLBP+ cell number was observed in the CTX of
Nf1BLBPCKO mice relative to wild-type mice. Cre-mediated Nf1 gene inactivation was confirmed by Cre immunohistochemistry and neurofibromin Western blotting
(Supplemental Fig. S2E). Collectively, these data demonstrate that Nf1 inactivation increases NSC proliferation
in a brain region-specific fashion.
Nf1 inactivation increases gliogenesis in the BS
To determine whether Nf1 loss in NSCs results in increased glial lineage differentiation in a brain region-

specific manner, we first quantified the number of Olig2+
glial progenitor cells in PN1 Nf1 / and wild-type NSCs
in vitro. The number of Olig2+ cells was increased by 2.4fold to fourfold in dissociated Nf1 / BS NSCs compared
with wild-type BS NSCs (Fig. 2A; Supplemental Fig. S3A).
Similar results were also observed using NSCs isolated
from the BS and CTX of E16 pups (Supplemental Fig. S3B).
We also noted a 1.2-fold increase in the number of Olig2+
cells following Nf1 loss in SVZ NSCs relative to wild-type
SVZ NSCs (Supplemental Fig. S3A). In contrast, there was
no significant change in Olig2+ cell number in NF1 /
CTX NSCs relative to wild-type CTX NSCs. Next, we
examined the number of Olig2+ cells in Nf1BLBPCKO
mice and control littermates in vivo. The brain regions
used for direct cell counting are illustrated in Figure 2B.
As observed in vitro, the number of Olig2+ cells was increased in the BS of PN8 (1.9-fold) and PN18 (1.5-fold)
Nf1BLBPCKO mice compared with wild-type littermates
in vivo (Fig. 2C,D).
To determine whether these Olig2+ cells represented
glial progenitor cells or committed oligodendrocyte lineage cells, we performed double-immunofluorescence
staining with Olig2 and established oligodendrocyte cell
lineage markers, including CC1 (APC), PDGFR-a, and
O4. First, we found that the number of APC (CC1)/Olig2
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Figure 2. Nf1 inactivation increases the
number of BS Olig2+ glial progenitors and
GFAP+ astrocytes. (A) The number of Olig2+
cells (red) was increased in Nf1 / BS NSCs
(Cre) compared with wild-type NSCs (LacZ).
No increases were observed in CTX NSCs.
Cells were counterstained with DAPI (blue).
(B) Schematic shows the brain regions used
for direct cell counting (blue). (CC) Corpus
callosum; (LV) lateral ventricle; (AC) anterior
commissure; (Vn) ventricle; (PnC) pontine
nucleus, caudal. (C) The number of Olig2+
glial progenitor cells was increased in the
BS of Nf1BLBPCKO mice at both PN8 and
PN18 compared with wild-type (WT) mice.
There was no increase in the number of
Olig2+ cells in the CTX of Nf1BLBPCKO mice.
Graphs show the number of Olig2+ cells per
surface area (0.1 mm2) (D). Increased numbers
of GFAP+ cells were observed in the BS of
Nf1BLBPCKO mice at both PN8 (E) and PN18
(F) compared with wild-type mice. There was
no increase in the number of GFAP+ cells in
the CTX of Nf1BLBPCKO mice. The number of
GFAP+ cells per surface area (0.1 mm2; left)
and fold change (Nf1BLBPCKO/WT; right) of
GFAP+ cells are graphically represented.
Values denote the mean 6 SEM. (*) P <
0.005; (**) P < 0.001; (***) P < 0.0001. Bars,
100 mm.

double-positive cells was not increased by Nf1 inactivation (Supplemental Fig. S3C). Second, the majority of
the Olig2+ cells increased in the BS of Nf1BLBPCKO
mice were not PDFR-a-immunoreactive (Supplemental
Fig. S3D). Third, following Nf1-deficient NSC differentiation in vitro, the Olig2 + cells were not O4+ (Supplemental Fig. S3E). Fourth, while we were unable to
perform NG2/Olig2 double-labeling experiments to
determine whether the Olig2+ cells were also NG2+, we
found that the total number of NG2+ cells was increased
in both CTX and BS of Nf1BLBP CKO mice compared
with wild-type controls (Supplemental Fig. S3F). Together, these data demonstrate that the Olig2 + cells
increased following BS NSC Nf1 inactivation are glial
progenitor cells, rather than committed oligodendrocyte
progenitors.
To determine whether the increase in Olig2+ cells
reflected an overall increase in gliogenesis, we quantified
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the number of GFAP+ cells (astrocytes) and found increased numbers of GFAP+ cells in the BS of Nf1BLBPCKO
mice at PN8 (63.5-fold) (Fig. 2E) and PN18 (5.6-fold) (Fig.
2F) compared with wild-type mice. In contrast, there was
no difference in the number of GFAP+ cells in the CTX or
SVZ (Supplemental Fig. 3G) of Nf1BLBPCKO mice relative
to wild-type controls. We confirmed these results using
additional astrocytic markers (clusterin [ApoJ] [Fagan
et al. 1999; Bachoo et al. 2004] and WT-1 [Schittenhelm
et al. 2008]): Increased numbers of WT-1+ and clusterin+
cells were observed in the BS, but not in the CTX, of
Nf1BLBPCKO mice (Supplemental Fig. S4A,B). Moreover,
the numbers of NeuN+ (neurons) and APC+ (oligodendrocytes) cells were not changed in either the CTX or the
BS of PN18 Nf1BLBPCKO mice relative to wild-type
mice (Supplemental Fig. S4C,D). These data demonstrate
that Nf1 inactivation increases gliogenesis specifically in
the BS.
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Ras activation increases NSC proliferation
and gliogenesis in the BS

The brain region-specific effects of Nf1 loss on NSC
proliferation and gliogenesis are Akt-dependent

Because Ras activity is increased in Nf1 / embryonic
NSCs (Dasgupta and Gutmann 2005), we examined the
activation state of the three different Ras isoforms (K-Ras,
H-Ras, and N-Ras) expressed in E11.5 NSCs following
Nf1 loss, and found increased activation of all three Ras
isoforms in Nf1 / NSCs relative to wild-type NSCs
(Supplemental Fig. S5A). To recapitulate Ras activation
by Nf1 loss in vitro, we infected PN1 NSCs from the CTX
and BS with either constitutively active K-Ras (KRas*) or
H-Ras (HRas*). The expression and activation of these
transduced Ras molecules were confirmed by Western
blotting and Ras activity assays (Supplemental Fig. S5B–
D). Similar to Nf1 / NSCs, only BS NSCs exhibited increased proliferation following either activated K-Ras
(1.9-fold) (Fig. 3A) or H-Ras (1.5-fold) (Fig. 3B) transduction. No increased proliferation was observed in CTX
NSCs following either K-Ras or H-Ras expression. To provide an in vivo correlate for these in vitro observations,
we also examined the effect of K-Ras activation on gliogenesis in PN18 Lox-stop-lox (LSL)-K-RasG12D; BLBP-Cre
(KRas*) mice. Similar to Nf1BLBPCKO mice (Fig. 2), KRas*
mice exhibited increased numbers of Olig2+ glial progenitor cells (1.9-fold) (Fig. 3C) and GFAP+ astrocytes (1.8fold) (Fig. 3D) in the BS, but not the CTX, compared with
wild-type mice. These data show that Ras activation in
NSCs recapitulates the brain region-specific effects of Nf1
loss on NSC proliferation and gliogenesis.

Because MAPK and Akt are the two major Ras downstream targets relevant to neurofibromin growth regulation, we measured their activation status in PN1 Nf1 /
and wild-type NSCs using phospho-specific antibodies.
Whereas MAPK activation was increased in both CTX
and BS Nf1-deficient NSCs relative to wild-type NSCs (Fig.
4A,B), Akt activation was increased only in Nf1 / NSCs
from the BS. In contrast, S6 activation (phospho-S6 [p-S6])
was not increased in either BS or CTX NSCs following Nf1
inactivation (Fig. 4A,B). Similar to Nf1 loss, increased Akt
activation was observed in BS, but not CTX, NSCs expressing either constitutively active K-Ras (KRas*) or
H-Ras (HRas*) compared with wild-type NSCs (Fig. 4C).
To determine whether induced expression of an activated Akt in brain NSCs would result in increased gliogenesis in both the BS and the CTX, we generated mice
with activated Akt (myr-Akt) expression in BLBP+ cells
(BLBP-Cre 3 LSL-myr-Akt mice [Akt* mice]) (Hegedus
et al. 2007). In contrast to Nf1BLBPCKO and KRas* mice,
Akt* mice exhibited increased numbers of Olig2+ cells in
both the CTX (1.7-fold) and the BS (1.4-fold) compared
with wild-type mice (Fig. 4D,G). Similarly, the number of
GFAP+ cells was also increased in both the CTX (threefold) and the BS (twofold) (Fig. 4E,G). Transgene expression was confirmed by GFP immunohistochemistry (Fig.
4F). Together, these data demonstrate that Akt activation
is the major determinant underlying the region-specific

Figure 3. Ras expression results in increased NSC proliferation and gliogenesis only in the BS. Neurosphere
size (NSC proliferation) was increased in KRas*expressing (A) and HRas*expressing (B) BS NSCs. There was no
increase in the diameters of KRas* or HRas* CTX NSCs.
(C) The number of Olig2+ cells was increased in the BS of
PN18 KRas* mice. There was no change in the number
of Olig2+ cells in the CTX. (D) The number of GFAP+
astrocytes was increased in the BS of KRas* mice. Olig2+
and GFAP+ cell numbers per surface area (0.1 mm2) are
graphically represented. Values denote the mean 6 SEM.
(*) P < 0.01. Bars: A,B, 500 mm; C,D, 100 mm.
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Figure 4. The region-specific effects of Nf1 loss on
NSC proliferation and gliogenesis are Akt-dependent. (A)
MAPK activation was increased in both CTX and BS
NSCs (PN1 Nf1flox/flox) after Nf1 inactivation (Cre). Infection with Ad5-LacZ (LacZ) was used as a wild-type
(WT) control. The level of activated Akt (Ser 473) was
increased only in BS Nf1 / (Cre) NSCs relative to wildtype (LacZ) BS NSCs. No change in p-S6 was observed. (B)
MAPK activation was increased in both CTX and BS
NSC cultures from Nf1BLBPCKO (CKO) mice. Increased
Akt activation was observed only in BS NSCs. No change
in p-S6 was observed. (C) Akt activation was similarly
increased only in BS NSCs expressing KRas* (2.6-fold
increase, P = 0.0034) and HRas*. The number of Olig2+
cells (D) as well as GFAP+ cells (E) was increased in both
the CTX and the BS of PN18 Akt*mice. (F) GFP immunohistochemistry shows that the Akt transgene is highly
expressed in the Akt* mouse brain. (G) The numbers of
Olig2+ and GFAP+ cells per surface area (0.1 mm2) are
quantitated. Values represent mean 6 SEM. (*) P < 0.05;
(**) P < 0.01. Bars, 100 mm.

effects of Nf1 inactivation on brain NSC proliferation and
gliogenesis.
Differential regulation of Akt by mTOR underlies
the brain region-specific effects of Nf1 loss
on NSC proliferation and gliogenesis
To determine the mechanism of differential Akt regulation in BS versus CTX NSCs, we first measured the levels
of numerous upstream regulators of Ras and Akt by
Western blotting (Fig. 5A) and quantitative RT–PCR
(qRT–PCR) (Supplemental Fig. S6A). We found no significant differences in p120 Ras-GAP, PTEN, or phosphoPDK1 expression in NSCs from the CTX versus the BS
(Fig. 5A), as well as no differences in Ppp2r2b (protein
phosphatase 2), Prkce (PKCe), Prkcq (PKCu), Tenc1 (C1-TEN),
Rasal2 (Ras protein activator-like 2), or Rasgrp1 (Ras-GRP)
mRNA expression in NSCs from the CTX versus the BS
(Supplemental Fig. S6A).
Next, we explored the possibility that mTOR complexes might differentially regulate Akt activity through
raptor or rictor function (Guertin and Sabatini 2007).
Using rapamycin to inhibit mTOR function in vitro,
Nf1 / BS NSC proliferation was reduced by twofold in
response to rapamycin treatment (0.5–1 nM), whereas
CTX NSC proliferation was not affected (Fig. 5B). In these
experiments, rapamycin treatment (1 nM) reduced Akt
hyperphosphorylation exclusively in BS NSCs, whereas
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S6 activation was inhibited in Nf1 / NSCs from both the
BS and CTX (Fig. 5B). To provide an in vivo correlate for
these in vitro findings, pregnant females and their resulting pups were treated with rapamycin, and the numbers
of Olig2+ and GFAP+ cells were quantified at PN8. Consistent with the hypothesis that mTOR regulates Aktmediated gliogenesis, we found that rapamycin treatment
reduced the number of Olig2+ (1.4-fold) and GFAP+ (2.1fold) cells in the BS of Nf1BLBPCKO mice (Fig. 5C). Similar
to Nf1 / NSCs, we found that Akt hyperactivation in
the BS of Nf1BLBPCKO mice was reduced following
rapamycin treatment in vivo, while S6 activation was
inhibited in both the BS and CTX in vivo (Fig. 5D).
Based on reports demonstrating that rictor-containing
mTOR complexes positively regulate Akt through Ser
473 phosphorylation (Hresko and Mueckler 2005), we
measured raptor and rictor expression in vitro and in vivo.
Surprisingly, rictor expression was higher in BS compared
wtih CTX in both NSC cultures (threefold) and brain
tissue (2.6-fold), whereas no differences in raptor expression were observed (Fig. 6A). To determine whether increased rictor expression in BS NSCs reflected differential
rictor/raptor transcription, we examined the mRNA
expression levels of rictor and raptor in CTX and BS
NSCs using qRT–PCR. No differences were observed in
the mRNA expression of rictor (P = 0.3962) or raptor (P =
0.7442) between CTX and BS NSCs.
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Figure 5. Region-specific effects of rapamycin on Nf1 / NSC proliferation and gliogenesis. (A) The levels of p120 Ras-GAP, PTEN,
and p-PDK1 are equivalently expressed in Nf1 / NSCs (Cre) compared with wild-type (LacZ). Western blotting of neurofibromin and
Cre recombinase shows loss of neurofibromin expression in Ad5-Cre-infected Nf1flox/flox NSCs. a-Tubulin was used as an internal
loading control. (B) Decreased Nf1 / BS NSC proliferation was observed following treatment with rapamycin. There was no effect of
rapamycin treatment (Cre + R) on CTX NSCs. Akt activation (Ser 473; p-Akt) was reduced to control levels in rapamycin-treated (1 nM)
Nf1 / BS NSCs. In both BS and CTX NSCs, S6 activation (p-S6) was inhibited by rapamycin treatment. (C) Decreased numbers of
Olig2+ glial progenitors and GFAP+ astrocytes were observed in the BS of PN8 Nf1BLBPCKO mice treated with rapamycin (CKO + R) in
vivo. (D) Akt activation was decreased following rapamycin treatment in the BS of Nf1BLBPCKO mice in vivo. p-S6 was inhibited by
rapamycin treatment in both the BS and CTX in vivo. Values represent mean 6 SEM. (*) P < 0.0001. Bar, 100 mm.

To determine whether mTOR/rictor function mediates
the increased proliferation and gliogenesis observed in
Nf1 / NSCs, we performed shRNAi knockdown (KD)
experiments. Rictor KD decreased the proliferation (as
assessed by direct counting and neurosphere diameter
measurements) and Akt activation of NF1 / BS NSCs to
wild-type levels, with no effect on Nf1 / CTX NSCs (Fig.
6B,C). Consistent with its role in TORC2 signaling, rictor
KD had no effect on S6 phosphorylation (Fig. 6C). In
contrast, raptor KD had no effect on Nf1 / BS NSC proliferation (neurosphere diameter and cell number) or gliogenesis (Olig2+ cell number) and did not change Akt activation (data not shown). Together, these results demonstrate
that the ability of BS NSCs to proliferate following Nf1 loss
results from mTOR/rictor-mediated Akt activation.
Since we observed no differential changes in the activation status of mTOR downstream effectors (PKCa, S6
kinase, S6, and 4EBP1) after Nf1 inactivation in the BS
versus the CTX (Supplemental Fig. S6B), we reasoned that
downstream targets of Akt, other than mTOR, must be
responsible for the increased proliferation of BS NSCs
following Nf1 loss. We first measured the activation status

of STAT3, FOXO1, and GSK3b in PN1 Nf1 / and wildtype NSCs from CTX and BS using phospho-specific
antibodies, but found no differential activation of these
signaling molecules. However, p27 expression was increased in Nf1 / CTX NSCs relative to wild-type CTX
NSCs, whereas no such increase was observed in Nf1 /
BS NSCs (Fig. 7A).
Previous studies have shown that p27 expression can be
regulated at both the transcriptional and post-translational
levels (Lin et al. 2009; Prasad et al. 2009). Whereas there
were no differences in p27 mRNA expression between
Nf1-deficient BS and CTX NSCs by qRT–PCR in vitro or in
vivo (P = 0.46), we found that p27 phosphorylation on both
Ser 10 and Thr 198 residues was increased following Nf1
loss exclusively in BS NSCs (Fig. 7B). Since increased p27
phosphorylation on Thr 198 and Ser 10 leads to its nuclear
export and subsequent degradation (Fujita et al. 2002;
Ishida et al. 2002), we ectopically expressed p27 in Nf1 /
BS NSCs by viral transduction to mimic the increased
p27 levels seen in Nf1 / CTX NSCs, and found that p27
expression reduced Nf1 / BS NSC proliferation to wildtype levels (Fig. 7C).
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Figure 6. Differences in mTOR regulation
of Akt underlie the brain region-specific differences in Nf1 / NSC proliferation. (A)
Rictor expression was higher in the BS compared with the CTX in vitro (NSCs; threefold) and in vivo (brain; 2.6-fold). There was
no difference in raptor expression. Results
were quantitated by scanning densitometry
using a-tubulin as an internal loading control. (B) Rictor silencing by lentiviral rictor
siRNA (siRNA) decreased neurosphere size
in Nf1 / BS NSC cultures. No change was
observed in Nf1 / CTX NSCs following
rictor silencing. Lentivirus-GFP (GFP) served
as a control for viral infection. (C) The fold
change in p-Akt and p-S6 (after normalization to total Akt and S6, respectively) relative
to wild-type (WT) controls is indicated below
the blots. Error bars denote the mean 6 SEM.
(*) P < 0.05; (**) P < 0.01. Bar, 500 mm.

To determine whether p27 phosphorylation was regulated by mTOR and Akt in Nf1 / BS NSCs, we examined
Thr 198 p27 phosphorylation following mTOR (rapamycin) and PI3-kinase (LY294002) inhibition. We found that
p27 phosphorylation was inhibited by rapamycin and
LY294002 in Nf1 / BS NSCs (Fig. 7D). Similarly, p27
phosphorylation at Ser 10 was also inhibited by rapamycin and LY294002 treatment in Nf1 / BS NSCs (data
not shown). Finally, using the identical lysates from the
experiment shown in Figure 6, B and C, we found that,

following rictor KD (but not raptor KD) (data not shown),
p27 expression was increased and p27 phosphorylation
(Thr 198) was decreased in Nf1 / BS NSCs (Fig. 7E).
These results demonstrate that mTOR/rictor/Akt regulates p27 function through phosphorylation in Nf1 /
NSCs (Fig. 7F), and collectively establish mTOR/rictormediated positive regulation of Akt activity as the major
determinant responsible for mediating the brain regionspecific effects of neurofibromin loss on NSC proliferation and gliogenesis.
Figure 7. Differential phosphorylation of
p27 results from mTOR/rictor/Akt-mediated
activation in Nf1 / BS NSCs. (A) p27 expression was increased exclusively in Nf1 /
BS NSCs compared with wild type, whereas
no regional difference in the level of phospho-STAT3, FoxO1, or GSK was observed
following Nf1 loss. Ad5-LacZ (LacZ) served
as a control for viral infection. (B) Nf1 loss
resulted in increased p27 phosphorylation
(p-p27; Ser 10 and Thr 198) in Nf1 / BS
NSCs. (C) Ectopic p27 expression in Nf1 /
BS NSCs restored proliferation to wild-type
levels. (D) p27 phosphorylation (p-p27; Thr
198) in Nf1 / BS NSCs was reduced by
rapamycin (1 nM) and LY294002 (20 mM)
treatment. (E) p27 expression in Nf1 / BS
NSCs was increased following rictor siRNA
silencing. In contrast, p27 phosphorylation
(Thr 198) in Nf1 / BS NSCs was reduced
following rictor siRNA treatment. No change
in p27 expression or phosphorylation was
observed following rictor KD in Nf1 / CTX
NSCs. a-Tubulin was included as an internal
loading control for Western blotting. (F) Rictor-mediated Akt activation regulates p27
phosphorylation and function in Nf1 / BS
NSCs. Error bars denote the mean 6 SEM.
(**) P < 0.01.
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Discussion
Neural stem cell functional diversity in the CNS is
dictated by the developmental age of the animal as well
as by spatially restricted signals present in specific brain
regions. In addition, NSCs from different regions of the
brain may be intrinsically distinct by virtue of cellautonomous properties innate to these unique NSC
populations. These brain region-specific cell-autonomous
differences are well illustrated by the NF1 tumor predisposition syndrome, in which gliomas most commonly
arise in the ON and BS, but rarely occur in the cortex. In
this study, we demonstrate that NSCs from the BS proliferate faster and differentiate into glial lineage cells
following Nf1 gene inactivation, whereas Nf1 loss in CTX
NSCs does not result in increased proliferation or gliogenesis. These differences do not reflect the mouse developmental age, as similar region-specific effects of Nf1
loss were observed in both embryonic and early postnatal
NSCs. Moreover, these differences were also found in
young mice in vivo following Nf1 inactivation in BLBP+
NSCs at E9.5. It is also unlikely that these differences
result from unique microenvironmental influences present
in the BS or CTX, since these brain region-specific differences were observed in isolated NSC populations in vitro.
Recently, we showed that astrocytes from the BS exhibit increased proliferation following Nf1 inactivation,
whereas no such increase in proliferation was observed in
Nf1-deficient neocortical astrocytes (Yeh et al. 2009). To
account for these brain region-specific responses to neurofibromin loss, we found that astrocytes from the CTX
expressed significantly less neurofibromin relative to
astrocytes from the BS and ON. Furthermore, Nf1 loss
in GFAP+ cells had no effect on neocortical astrocyte
proliferation in vitro or astrocyte numbers in vivo. In
contrast to astrocytes, we found no differences in Nf1
gene or neurofibromin protein expression between NSCs
from the CTX and the BS. This finding implicates other
mechanisms in dictating the response of NSCs from
different brain regions to Nf1 inactivation.
To identify the mechanism underlying the brain regionspecific effect of Nf1 loss on NSC function, we sought to
determine whether constitutive RAS activation in NSCs
in vitro and in vivo could mimic the effects of neurofibromin loss. The finding that RAS activation in NSCs
similarly increases NSC proliferation and gliogenesis in
an identical brain region-specific manner supports the
notion that RAS hyperactivation is the primary driver
of NSC proliferation and glial differentiation following
Nf1 gene inactivation. In contrast to Nf1 / astrocytes in
which only K-RAS hyperactivation was observed (Dasgupta
et al. 2005a), neurofibromin loss in NSCs results in increased activity of all three RAS isoforms (H-RAS, K-RAS,
and N-RAS). While we found that both activated K-RAS and
H-RAS expression in NSCs led to increased BS (but not
CTX) NSC proliferation, it is not clear whether the three
RAS isoforms perform overlapping redundant functions
with respect to NSC function. Current studies are focused
on exploring the consequences of N-RAS activation on
NSC function in the BS and CTX in vitro and in vivo.

Next, we determined whether differential Akt activation was responsible for the observed differences in NSC
behavior. Akt is a potent regulator of NSC proliferation in
many brain regions (Otaegi et al. 2006; Peltier et al. 2007),
such that hyperactivation of PI3-kinase and Akt increases
the proliferation of Pten-deficient NSCs (Groszer et al.
2001). We showed previously that Akt activation was
increased in Nf1-deficient embryonic NSCs (Dasgupta
and Gutmann 2005), and that activated Akt expression
in BLBP+ cells resulted in increased gliogenesis in vivo
(Hegedus et al. 2007). In the present study, we found differential Akt activation in BS NSCs relative to NSCs
from the CTX. This brain region-specific Akt activation
was also observed following K-RASG12D and H-RASG12V
expression in NSCs in vitro or K-RASG12D expression
in BLBP+ cells in vivo (data not shown), suggesting that
deregulated neurofibromin/RAS signaling in NSCs is not
responsible for the differences in brain region-specific
NSC Akt activation. In contrast, expression of activated
Akt in BLBP+ cells in vivo was sufficient to increase BLBP+
NSC numbers and gliogenesis, arguing that Akt activation
alone accounts for the brain region-restricted differences in
Nf1 / NSC behavior. The observation that Akt is a central
driver of gliogenesis is consistent with prior reports
demonstrating that inhibition of PI3-kinase/Akt activation with LY294002 decreased the number of GFAP+ cells
in the olfactory bulb (Otaegi et al. 2006) as well as changed
the subcellular localization of Olig2, which is critical for
the induction of astrocyte differentiation (Setoguchi and
Kondo 2004).
In this study, we determined that BS-specific NSC Akt
activation results from differences in mTOR regulation.
mTOR forms complexes with raptor and rictor to negatively and positively regulate Akt activity, respectively
(Guertin and Sabatini 2007). The mTOR complex containing rictor (TORC2) positively regulates Akt activity
through phosphorylation on Ser 473 (Hresko and Mueckler
2005; Sarbassov et al. 2005), which can be inhibited by
rapamycin treatment (Sarbassov et al. 2006). Our finding
that raptor and rictor are expressed at different levels in
BS versus CTX NSCs is further underscored by an examination of publically available Unigene EST expression
data sets: In both mouse and human tissues, rictor levels
were higher than raptor levels in several tissues, whereas
raptor expression predominated in other tissues (DY Lee
and DH Gutmann, unpubl.; http://www.ncbi.nlm.nih.gov/
UniGene/ESTProfileViewer). The consequence of this differential rictor expression is preferential Akt activation in
BS NSCs, such that pharmacologic (rapamycin inhibition)
or genetic silencing with rictor KD restores Nf1 / BS
NSC proliferation and gliogenesis to wild-type levels.
Previously, we found increased mTOR activation in
Nf1 / astrocytes and Nf1-deficient mouse optic gliomas
(Dasgupta et al. 2005b; Sandsmark et al. 2007). In astrocytes, mTOR regulates cell growth by activating Rac1,
rather than by activating Akt, as seen in NSCs. This observation argues that different cell types in the CNS
employ mTOR pathway signaling in unique fashions
to regulate cell growth. These critical distinctions must
be considered when designing therapies to target brain
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tumors. In this regard, rictor is overexpressed in gliomas,
resulting in Akt hyperactivation (Masri et al. 2007), and
PI3-kinase/Akt, but not mTOR, signaling regulates stem
cell-like phenotypes in gliomas (Bleau et al. 2009).
Based on the observation that mTOR acts solely as a
regulator of Akt function in NSCs, we examined Akt
downstream targets that are regulated by Akt. No changes
in GSK3b, FOXO1, S6, S6K, 4EBP1, PKCa, and STAT3
phosphorylation were found in Nf1 / BS NSCs relative to
those from the CTX. In contrast, we found increased
expression of the p27 cyclin-dependent kinase inhibitor
following Nf1 inactivation in CTX NSCs, but not in BS
NSCs. p27 function is regulated by Akt-mediated phosphorylation at residues Thr 198 and Ser 10, resulting in
cytoplasmic localization and inhibition of its activity
(Fujita et al. 2002; Motti et al. 2004; Crean et al. 2006).
Akt also regulates Skp2 (S-phase kinase-associated protein2), a SCF F-box protein, which binds to p27 and targets it
for ubiquitination and degradation (Lin et al. 2009). Consistent with a model in which mTOR/rictor-mediated Akt
activation in Nf1 / BS NSCs results in down-regulation
of p27 expression, we identified an Akt-dependent increase
in p27 phosphorylation (Ser 10 and Thr 198) and a reduction in nuclear (active) p27 in Nf1 / BS, but not CTX,
NSCs (DY Lee and DH Gutmann, unpubl.). Second, p27 reexpression in Nf1 / BS NSCs restored proliferation to
levels observed in wild-type BS NSCs. Third, p27 induction (as seen in Nf1 / CTX NSCs) was observed only in
Nf1 / BS NSCs following rictor shRNAi silencing. These
findings establish mTOR/rictor/Akt regulation of p27
function as a key determinant of Nf1-deficient brain
region-specific NSC proliferation and differentiation.
The relevance of p27 to gliomagenesis is further underscored by several observations: First, p27 loss in O2A glial
progenitors results in a 2.6-fold increase in the number
of GFAP+ astrocytes generated following in vitro differentiation and a 2.8-fold increase in p27-null mice in vivo
(Casaccia-Bonnefil et al. 1997). Second, p27 loss in mice
increases the number and proliferation of transient amplifying (type C) neuroglial progenitors in the SVZ in vivo
(Doetsch et al. 2002). Third, mutant epidermal growth
factor receptor (EGFR) signaling, as observed in some
high-grade gliomas, has been shown to regulate glioma
cell growth by suppressing p27 expression through activation of the PI3-kinase/Akt pathway (Narita et al. 2002).
While these findings provide compelling support for p27
as a critical downstream Akt effector that controls NSC
proliferation and perhaps gliomagenesis, it is also possible
that other molecules are involved in specifying glial
differentiation. In this regard, Akt is known to regulate
gliogenesis by modulating the phosphorylation/expression of specific transcription factors important for glial
differentiation, including N-CoR and Olig2 (Hermanson
et al. 2002; Setoguchi and Kondo 2004). Future studies
will be required to address the role of these Akt-regulated
transcription factors in gliogenesis and glioma formation.
Our finding that Nf1 loss results in increased numbers
of Olig2+ cells is important in light of several recent reports implicating Olig2 in gliomagenesis. First, Olig2 is
expressed universally in diffuse gliomas (Ligon et al. 2004),
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including low-grade pilocytic astrocytomas, such as those
arising in children with NF1 (Takei et al. 2008). Second,
the vast majority of the proliferating cells in diffuse
gliomas are Olig2+ cells (Rhee et al. 2009). Third, Olig2
function is required for neuroglial progenitor proliferation
as well as astrocytoma formation in genetically engineered
mouse glioma models in vivo (Ligon et al. 2007). Collectively, these observations, coupled with our findings, suggest a critical role for this population of neuroglial progenitors in glioma development.
Over the last several years, it has become widely
recognized that neural stem cells residing in the SVZ of
adults may be the cell of origin for gliomas (Jackson et al.
2006; Alcantara Llaguno et al. 2009). In these studies,
targeting NSCs in the SVZ niche with glioma-associated
oncogenic mutation or tumor suppressor gene inactivation is sufficient for gliomagenesis. It was therefore unanticipated that Nf1 loss in SVZ NSCs in vitro and in vivo
resulted in more modest increases in proliferation and
Olig2+ progenitor cell generation. While further experimentation will be required, it is possible that different
stem cell niches are uniquely affected by both the specific
cancer-associated genetic change (Nf1 loss vs. combined
Nf1, p53, and Pten inactivation) and the developmental
age of the animal (young vs. adult mice). These determinants may be particularly relevant to the distinct spatial
and temporal pattern of gliomagenesis in patients with
NF1 (optic pathway and BS gliomas arising in children
<10 yr of age) (Listernick et al. 2007).
In summary, we provide a mechanistic explanation for
the differential response of spatially distinct populations
of brain NSCs to neurofibromin loss. These findings are
particularly germane to glioma formation in children
with NF1, whose brain tumors usually develop in the
optic pathway and BS, but rarely in the cortex. We showed
recently that stromal signals expressed by microglia (meningioma-expressed antigen-5 [MGEA5]) or multiple other
cellular elements (CXCL12) in a spatially restricted fashion along the optic pathway uniquely promote the proliferation and survival of Nf1-deficient, but not wild-type,
astrocytes (Daginakatte and Gutmann 2007; Warrington
et al. 2007). In this regard, we propose that tumor formation requires a permissive microenvironment composed of
cell types and molecular signals that facilitate cell growth
in receptive preneoplastic cell populations. Our demonstration of a receptive preneoplastic cell type defined by
differential mTOR-mediated Akt activation broadens our
understanding of the mechanisms underlying NSC heterogeneity, and offers new insights relevant to the design
of future therapeutics that target specific populations of
cancer cells.
Materials and methods
Mice
BLBP-Cre transgenic mice were intercrossed with Nf1flox/flox
mice to generate BLBP-Cre; Nf1flox/flox (Nf1BLBPCKO) mice. To
generate transgenic mice that express KRas* or Akt*, BLBP-Cre
transgenic mice were intercrossed with LSL-K-RasG12D mice and
LSL-myr-Akt mice, respectively. All strains were maintained on
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a C57BL/6 background and used in accordance with approved
animal studies protocols at Washington University.
Culture of NSCs and generation of Nf1

/

neurospheres

CTX and BS regions were dissected from PN1 mouse pups as
well as E13.5 mouse embryos of each genotype, and NSCs were
generated as reported previously (Dasgupta and Gutmann 2005).
Briefly, CTX tissues were derived from the somatosensory cortex, excluding the white matter tracts and the corpus callosum,
while BS tissues included the midbrain, pons, and medulla after
careful removal of the cerebellar peduncles (Fig. 2B). NSCs from
Nf1flox/flox mouse brains were treated with Ad5-Cre or Ad5-LacZ
diluted in NSC medium. After loss of neurofibromin, expression
was verified by Western blotting.
Measurement of NSC proliferation
At least 10 neurospheres from each genotype were trypsinized
and plated into individual wells of ultralow-binding 24-well
plates with complete NSC medium containing EGF and FGF.
After 10–12 d, the size (diameter) of the resulting secondary
neurospheres was determined using Metamorph 7.1 (Molecular
Devices).
Generation of NSCs expressing constitutively active K-Ras
and H-Ras
K-Ras-expressing NSCs were generated by infecting PN1 LSLK-RasG12D neurospheres with Ad5-Cre. As a control, NSCs isolated from wild-type mouse brains were infected with Ad5-Cre.
H-Ras-expressing NSCs were generated following infection with
MSCV containing H-RasG12V (MSCV-H-RasG12V-GFP). MSCVGFP was used as a control for these experiments.

For the in vivo experiments, rapamycin (1 mg/kg per day) was
injected intraperitoneally into pregnant females from E16 to E18.
Postnatally, 0.5 mg/kg rapamycin was injected subcutaneously
at PN1 and PN3, and the pups were perfused at PN8.
Retrovirus infection
Rictor siRNA (NM030168.2; TRCN0000123397) or GFP-containing pLKO.1 plasmid was cotransfected with VSV-G and D8.9
helper DNA into HEK293T cells using the FuGENEHD transfection reagent (Roche). p27-MSCV was cotransfected with
T-helper DNA into HEK293T cells. Nf1 / neurospheres (Ad5Cre-infected Nf1flox/flox cells) were dissociated into single cells by
trypsin and transduced with viral supernatants from HEK293T
cells. Transfection efficiency was evaluated by Western blotting.
Each experiment was performed at least two times with identical
results.
Statistical analysis
Each experiment was performed with samples from at least three
independent groups. Statistical significance (P < 0.05) was determined using the Student’s t-test and GraphPad Prism 4.0
software (GraphPad, Inc.).
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